Macropore Inc. IR-Pages
MacroPore Biosurgery Enters Agreement for Thin Film Distribution Rights in Japan
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
MacroPore Biosurgery Enters Agreement with Senko Medical for Thin Film
Distribution Rights in Japan
– Deal includes additional upside through minimum purchase requirements and
royalties –
San Diego, CA, July 19, 2004 – MacroPore Biosurgery, Inc. (Frankfurt: XMP)
(Reuters: MACP.DE) (Bloomberg: XMP) today announced that it has granted Senko
Medical Trading Co. (Senko) exclusive sales and distribution rights to the thin
film product line, including SurgiWrap(TM) and CardioWrap(TM), in Japan.
In return for these rights, MacroPore Biosurgery will receive from Senko up to
$3.0 million in payments, which includes an upfront $1.5 million license fee,
$1.25 million upon submission of a regulatory application to the Japanese
Ministry of Health, Labour and Welfare (MHLW), and $250,000 upon product
approval by MHLW. In addition, the agreement represents potential upside for
MacroPore Biosurgery in revenues from minimum purchase requirements and
royalties on Senko’s gross revenues for a three year-period following initiation
of commercialization of the products in Japan, which potentially represents
$9.0 to $10.0 million in revenue to MacroPore Biosurgery over that term.
end of ad-hoc-announcement (c)DGAP 19.07.2004
Issuer’s information/explanatory remarks concerning this ad-hoc-announcement:
“The Senko team looks forward to having MacroPore Biosurgery as our partner in
Japan and to introducing the thin film family of products to the Japanese
market,” said Mr. Tetsuo Sasaki, President of Senko. “We will make every effort
to assure success for both companies.”
“We are pleased to establish Senko, one of Japan’s leading medical product
distributors, as our distribution partner in Japan, which represents the second
largest medical market in the world,” said Seijiro Shirahama, Vice President,
Asia Pacific at MacroPore Biosurgery. “Because of their broad channels of
distribution and enthusiasm for these products, we are very fortunate to have
the distribution of our thin film products in their capable hands.”
MAST Biosurgery AG (MAST), who purchased the non-Japanese thin film business
from MacroPore Biosurgery in May 2004, continues to hold an option to acquire
the rights to the thin film product line for the Japanese market from MacroPore
Biosurgery. If MAST should exercise the option, they would have to make a
material payment to MacroPore Biosurgery and then the two companies would share
in MAST’s gross profits and royalties from Senko for a three-year period
following initiation of commercialization of the products in Japan. MacroPore
Biosurgery continues to hold an exclusive worldwide license for bioresorbable
thin films for the spinal market and a perpetual nonexclusive worldwide license
to bioresorbable thin films in connection with regenerative cell technology.
About MacroPore Biosurgery, Inc.
MacroPore Biosurgery (Frankfurt: XMP) is focused on the discovery, development
and commercialization of regenerative medicine technologies. We have two
technology platforms, bioresorbable technology and regenerative cell technology.
Our surgical implants, derived from our bioresorbable technology, represent one
of the latest advancements in spine and orthopedic medicine. They are
manufactured by us and distributed exclusively through Medtronic Sofamor Danek.
Within our regenerative cell technology program, we are developing a system to
isolate autologous, homologous-use, regenerative cells. Simultaneously, we are
generating scientific knowledge through internal research to support the
clinical use of these cells. Our most advanced research and development program
is in the repair of cardiovascular tissues that are damaged after a heart
attack. We are also researching applications in bone repair, spinal disc
regeneration, and cosmetic and reconstructive surgery. For further information
please visit our web site http://www.macropore.com .
Cautionary Statement Regarding Forward-Looking Statements
This press release may include forward-looking statements regarding events and
trends which may affect MacroPore Biosurgery’s future operating results and
financial position. Such statements are subject to risks and uncertainties that
could cause MacroPore Biosurgery’s actual results and financial position to
differ materially. These risks and uncertainties are described (under the
heading “Risk Factors”) in our 2003 Form 10-K annual report for the year ended
December 31, 2003, which is available on our web site. MacroPore Biosurgery
assumes no responsibility to update any revision of forward-looking statements
to reflect events, trends or circumstances after the date they are made.
Contact:
MacroPore Biosurgery, Inc.
Tom Baker
Media & U.S. Investors
Tel. +1-858-458-0900
tbaker@macropore.com
MacroPore Biosurgery, Inc.
Stefanie Bacher
European Investors
Tel. +1-858-362-0365
sbacher@macropore.com
edicto GmbH
Axel Mühlhaus/Sönke Knop
European Investor &
Press Agency
Tel.: +49 (0) 60 84 94 85-90
kontakt@edicto.de
——————————————————————————–
WKN: 940682; ISIN: USU553961025; Index: NEMAX 50
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-
Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart
191600 Jul 04
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden